Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 15 16 17 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Ochre Bio–Hermes-Epitek: investment, 202106 seed financing round totalling $9.6m incl co-investor Hermes-Epitek 2021-06-16
Ochre Bio–Hoxton Ventures: investment, 202106 seed financing round totalling $9.6m incl co-investor Hoxton 2021-06-16
Ochre Bio–Khosla Ventures: investment, 202106 seed financing round totalling $9.6m incl lead investor Khosla Ventures 2021-06-16
Ochre Bio–Selvedge: investment, 202106 seed financing round totalling $9.6m incl co-investor Selvedge 2021-06-16
Ochre Bio–SEVERAL: investment, 202106 seed financing round $9.6m led by Khosla Ventures 2021-06-16
Alentis Therapeutics–Bellevue: investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor BB Pureos Bioventures 2021-06-15
Alentis Therapeutics–BioMedPartners: investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor BioMed Partners 2021-06-15
Alentis Therapeutics–France (govt): investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor Bpifrance InnoBio 2 Fund 2021-06-15
Alentis Therapeutics–High-Tech Gründerfonds: investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor HTGF 2021-06-15
Alentis Therapeutics–Jeito Capital: investment, 202106 financing round Series B totalling CHF60m incl new + co-investor Jeito Capital 2021-06-15
Alentis Therapeutics–Morningside: investment, 202106 financing round Series B totalling CHF60m incl new + lead investor Morningside Ventures 2021-06-15
Alentis Therapeutics–Schroders: investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor Schroders Capital 2021-06-15
Alentis Therapeutics–SEVERAL: investment, 202106 financing round Series B CHF60m led by Morningside Venture Investments 2021-06-15
Allcyte–Exscientia: investment, 202106– acquisition €50m in cash + ordinary shares ANNOUNCED 2021-06-15
Capsida Biotherapeutics–CRISPR Therapeutics: gene therapy, 202106– strategic collab AAV-based gene therapies for ALS + Friedreich’s Ataxia 2021-06-15
Quadira Biosciences–Veraxa Biotech: antibody-drug conjugates, 202106– collab developm €na using 3D CoSeedis platform + microfluidics technology 2021-06-14
Atai Life Sciences–SEVERAL: investment, 202106 IPO $225m+$33.75m with 15m+2.25m common shares at $15/share at Nasdaq Global Market 2021-06-11
ITM–FRIBA Investment: investment, 202106 financing round totalling €25m incl new investor FRIBA Investment 2021-06-10
ITM–Portland Holdings: investment, 202106 financing round totalling €25m incl investor Portland Holdings 2021-06-10
ITM–SEVERAL: investment, 202106 financing round €25m private equity incl Portland Holdings + FRIBA Investment 2021-06-10
Kojin Therapeutics–Bayer: investment, 202106 financing round Series A totalling $60m incl co-investor Leaps by Bayer 2021-06-09
Kojin Therapeutics–SEVERAL: investment, 202106 financing round Series A $60m co-led by Polaris Partners + Newpath Partners + Cathay Health 2021-06-09
Boehringer–Lifebit: Lifebit REAL platform, 202106– collab long-term using NLP + AI for detection + early reporting of infectious disease outbreaks 2021-06-08
Avi Medical–SEVERAL: investment, 202106 financing round Series A €28.5m led by Heal Capital + Addition 2021-06-07
Innovative Molecules–Akampion: public relations, 202106 service existent by Akampion 2021-06-07
Innovative Molecules–Life Sciences Partners: investment, 202106 financing round Series A totalling €20m incl lead investor LSP 2021-06-07
Innovative Molecules–SEVERAL: investment, 202106 financing round Series A €20m led by LSP 2021-06-07
MedXCell–PERSON: investment, 202106 financing round Series A totalling CHF5.3m incl new + lead investor Anh Nguyen 2021-06-04
MedXCell–SEVERAL: investment, 202106 financing round Series A CHF5.3m led by Anh Nguyen + incl other private investors 2021-06-04
Corat Therapeutics–Germany (govt): grant, 202106– up to €7m grant from BMBF from Covid-19 drug programme 2021-06-03
Corat Therapeutics–Lower Saxony (govt): investment, 202106 3rd financing round totalling €5.7m? incl existing investor NBank Capital 2021-06-03
Corat Therapeutics–OTHER: investment, 202106 3rd financing round totalling €5.7m? incl private investors from Braunschweig 2021-06-03
Corat Therapeutics–SEVERAL: investment, 202106 3rd financing round €5.7m? from NBank Capital + private investors 2021-06-03
AstraZeneca–Celonis: management execution software, 202106 supply existent customer AstraZeneca 2021-06-02
AstraZeneca–Proteros: small-molecule cancer drugs, 202106– collab RnD + license agreem with research funding + $62m milestones + royalties 2021-06-02
Celonis–Arena Holdings: investment, 202106 financing round Series D totalling $1b incl existing + co-investor Arena Holdings 2021-06-02
Celonis–Durable Capital: investment, 202106 financing round Series D totalling $1b incl new + co-lead investor Durable Capital Partners LP 2021-06-02
Celonis–Franklin Templeton: investment, 202106 financing round Series D totalling $1b incl new + co-investor Franklin Templeton 2021-06-02
Celonis–SEVERAL: investment, 202106 financing round Series D $1b co-led by Durable Capital Partners + T Rowe Price 2021-06-02
Celonis–Splunk Ventures: investment, 202106 financing round Series D totalling $1b incl new + co-investor Splunk Ventures 2021-06-02
Celonis–T Rowe Price: investment, 202106 financing round Series D totalling $1b incl new + co-lead investor funds+accounts managed by T Rowe Price 2021-06-02
Constellation–Centerview Partners: financial services, 202106 supply service Centerview Partners is financial advisor for acquisition by MorphoSys 2021-06-02
Constellation–MorphoSys: investment, 202106–202107 acquisition cash tender offer $1.7b at $34/share by MorphoSys 2021-06-02
Constellation–Wachtell Lipton: legal services, 202106 supply service Wachtell Lipton is legal advisor regarding acquisition by MorphoSys 2021-06-02
Danaher–Celonis: management execution software, 202106 supply existent customer Danaher Corp 2021-06-02
Gilde Investment–LifeSci: public relations, 202106 supply service existent LifeSci Advisors is media contact for Gilde Healthcare 2021-06-02
GoSilico–Danaher: investment, 202106 acquisition of GoSilico GmbH by Cytiva 2021-06-02
GSK–Celonis: management execution software, 202106 supply existent customer GSK 2021-06-02
L’Oréal–Celonis: management execution software, 202106 supply existent customer L’Oréal 2021-06-02
MorphoSys–Goldman Sachs: financial services, 202106 supply service GS Bank Europe SA is financial advisor with regard to acquisition of Constellation 2021-06-02
MorphoSys–Royalty Pharma: credit, 202106– up to $350m development funding bonds over 1-year period 2021-06-02
MorphoSys–Royalty Pharma: investment, 202106–202107 capital increase $100m excl subscription rights resulting in 3.9% shareholding for Royalty Pharma 2021-06-02
MorphoSys–Skadden Arps: legal services, 202106 supply service Skadden Arps Slate Meagher & Flom is legal advisor for acquisition of Constellation 2021-06-02
Pfizer–Celonis: management execution software, 202106 supply existent customer Pfizer 2021-06-02
Royalty Pharma–Goodwin Procter: legal services, 202106 supply service Goodwin is legal advisor regarding royalty + licensing agreem with MorphoSys 2021-06-02
Royalty Pharma–MorphoSys: guselkumab + otilimab et al, 202106– acquisition royalty/milestone rights $1.425b upfront + $150m milestones by Royalty 2021-06-02
Siemens–Celonis: management execution software, 202106 supply existent customer Siemens 2021-06-02
BioVersys–CARB-X: grant, 202106– award non-dilutive funding $4.35m for antibiotics RnD with possibility for additional $10.98 milestone-related 2021-06-01
Inovedis–High-Tech Gründerfonds: investment, 202106 seed financing round totalling €1.8m incl lead investor HTGF 2021-06-01
Inovedis–SEVERAL: investment, 202106 seed financing round €1.8m led by HTGF 2021-06-01
Araxa Biosciences–Velabs Therapeutics: investment, 202105 acquisition of Araxa by Velabs company renamed Veraxa Biotech GmbH 2021-05-31
Ada Health–Bayer: investment, 202105 financing round Series B totalling $90m incl lead investor Leaps by Bayer 2021-05-27
Ada Health–F4: investment, 202105 financing round Series B totalling $90m incl co-investor F4 2021-05-27
Ada Health–Inteligo Bank: investment, 202105 financing round Series B totalling $90m incl co-investor Inteligo Bank 2021-05-27
Ada Health–Mutschler Ventures: investment, 202105 financing round Series B totalling $90m incl co-investor Mutschler Ventures 2021-05-27
Ada Health–Samsung: investment, 202105 financing round Series B totalling $90m incl co-investor Samsung Catalyst Fund 2021-05-27
Ada Health–SEVERAL: investment, 202105 financing round Series B $90m led by Leaps by Bayer 2021-05-27
Ada Health–Vitruvian Partners: investment, 202105 financing round Series B totalling $90m incl co-investor Vitruvian Partners 2021-05-27
BrainRepair–PERSON: investment, 202105 investment Metin Colpan acquires 5% of shares of BrainRepair worth €15m 2021-05-27
Origin.bio–Acequia Capital: investment, 202105 financing round totalling $15m incl new + co-investor Acequia Capital 2021-05-26
Origin.bio–BY Capital: investment, 202105 financing round totalling $15m incl existing + co-investor BlueYard Capital 2021-05-26
Origin.bio–EQT: investment, 202105 financing round totalling $15m incl lead investor EQT Ventures 2021-05-26
Origin.bio–Inventures: investment, 202105 financing round totalling $15m incl new + co-investor Inventures 2021-05-26
Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Charlie Songhurst 2021-05-26
Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Sten Tamkivi 2021-05-26
Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Taavet Hinrikus 2021-05-26
Origin.bio–SEVERAL: investment, 202105 financing round $15m led by EQT Ventures 2021-05-26
Haya Therapeutics–4See Ventures: investment, 202105 seed financing round totalling CHF18m incl co-investor 4See Ventures 2021-05-20
Haya Therapeutics–Apollo Health Ventures: investment, 202105 seed financing round totalling CHF18m incl co-investor Apollo HV 2021-05-20
Haya Therapeutics–Bernina BioInvest: investment, 202105 seed financing round totalling CHF18m incl co-investor Bernina BioInvest 2021-05-20
Haya Therapeutics–Bioscribe: public relations, 202105 service existent by Bioscribe 2021-05-20
Haya Therapeutics–Broadview Ventures: investment, 202105 seed financing round totalling CHF18m incl lead investor Broadview Ventures 2021-05-20
Haya Therapeutics–Schroders: investment, 202105 seed financing round totalling CHF18m incl co-investor Schroder Adveq 2021-05-20
Haya Therapeutics–SEVERAL: investment, 202105 seed financing round CHF18m led by Broadview Ventures 2021-05-20
Haya Therapeutics–Univ Lausanne: RNA-targeting drug, 202105 license excl existent for lncRNA Wisper targeting drug from CHUV 2021-05-20
Haya Therapeutics–Viva Biotech: investment, 202105 seed financing round totalling CHF18m incl co-investor Viva BioInnovator 2021-05-20
Numab–BlackRock: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor funds/accounts managed by BlackRock 2021-05-20
Numab–BVF Partners: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor BVF Partners LP 2021-05-20
Numab–Cormorant Asset Management: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor Cormorant AM 2021-05-20
Numab–Forbion: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor Forbion Growth Opportunities Fund 2021-05-20
Numab–HBM: investment, 202105 financing round Series C totalling CHF100m incl new + co-lead investor HBM Partners 2021-05-20
Numab–Novo Group: investment, 202105 financing round Series C totalling CHF100m incl new + co-lead investor Novo Holdings 2021-05-20
Numab–Octagon Capital: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor Octagon Capital Advisors 2021-05-20
Numab–RTW Investments: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor RTW investments LP 2021-05-20
Numab–SEVERAL: investment, 202105 financing round Series C CHF100m co-led by new investors Novo Holdings + HBM Partners 2021-05-20
Swixx Biopharma–HBM: investment, 202105– capital increase totalling €45m incl €5m from existing investor HBM Healthcare Investments 2021-05-20
Swixx Biopharma–Mérieux: investment, 202105– capital increase totalling €45m incl €40m for minority share from new investor MxEP 2021-05-20
Swixx Biopharma–SEVERAL: investment, 202105– capital increase €45m with €40m from new investor MxEP + €5m from existing investor HBM 2021-05-20
Nanoscribe–Cellink: investment, 202105 acquisition 100% of Nanoscribe Holding for preliminary €36.9m with €24.7m cash + €12.2m in Series B shares 2021-05-19
Hummingbird Bioscience–Bellevue: investment, 202105 financing round Series C totalling $125m incl new + co-investor Pureos Bioventures 2021-05-18
next pagenext page 1 2 3 ... 15 16 17 ... 33 34 35  next pagenext page



Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top